Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Adam, Pettinger"'
Publikováno v:
IEEE Robotics and Automation Letters. 7:7224-7231
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::374d3946e2005cae96d1fc69aace7ed9
https://doi.org/10.1109/lra.2022.3181732
https://doi.org/10.1109/lra.2022.3181732
Autor:
Ann S. LaCasce, Matthew J. Maurer, Kristie A. Blum, Nancy L. Bartlett, David D. Hurd, Adam Pettinger, John C. Byrd, Francisco J. Hernandez-Ilizaliturri, Wendy Stock, Lawrence D. Kaplan, Noreen Fulton, Amy S. Ruppert, David Scott, John P. Leonard, Bruce D. Cheson, Eric D. Hsi, Yi Tian Liu
Publikováno v:
Am J Hematol
Immunochemotherapy followed by autologous transplant (ASCT) in CALGB/Alliance 59909 achieved a median progression-free survival (PFS) in mantle cell lymphoma (MCL) of 5 years, but late recurrences occurred. We evaluated tolerability and efficacy of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab590845b188a2dc336fcf0235a46c83
https://pubmed.ncbi.nlm.nih.gov/32170769
https://pubmed.ncbi.nlm.nih.gov/32170769
Autor:
Diane F. Jelinek, Jeremy T. Larsen, Charla R. Secreto, Jose F. Leis, Thomas M. Habermann, Deborah J. Bowen, Betsy LaPlant, Connie Lesnick, T. G. Call, Charles Erlichman, Curtis A. Hanson, Tait D. Shanafelt, Craig B. Reeder, Neil E. Kay, Daniel A. Nikcevich, Renee C. Tschumper, Justin C. Boysen, Adam Pettinger, Wei Ding, Michael S. Conte
Publikováno v:
American Journal of Hematology. 92:759-763
Akt is a downstream target of B cell receptor signaling and is a central regulator of CLL cell survival. We aim to investigate the safety and efficacy of the Akt inhibitor MK-2206 in combination with bendamustine and rituximab (BR) in relapsed and/or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d8d3dead857f310ec685f4b8d177445b
https://doi.org/10.1002/ajh.24762
https://doi.org/10.1002/ajh.24762
Completing Complex Contact Tasks Using Integrated Active and Passive Compliant Control Methodologies
Autor:
Mitch Pryor, Adam Pettinger
Publikováno v:
Volume 3, Rapid Fire Interactive Presentations: Advances in Control Systems; Advances in Robotics and Mechatronics; Automotive and Transportation Systems; Motion Planning and Trajectory Tracking; Soft Mechatronic Actuators and Sensors; Unmanned Ground and Aerial Vehicles.
In this paper we introduce the Generalized Contact Control Framework (GCCF) implemented on a compliant robotic manipulator. We demonstrate that the combined joint compliance and GCCF-based compliance control enable the completion of complex contact t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a29d6611ad97e0da82b426fb67992a88
https://doi.org/10.1115/dscc2019-9062
https://doi.org/10.1115/dscc2019-9062
Publikováno v:
CASE
Robotic tool changers allow the use of multiple tools or end-effectors by a robotic manipulator and eliminate the need for human intervention to change tools. In this paper, we present the design and testing of a passive mechanical tool changer desig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e693cbcbd7fa5e12b0c81431f9d2f29b
https://doi.org/10.1109/coase.2019.8843255
https://doi.org/10.1109/coase.2019.8843255
Autor:
Jose F. Leis, Adam Pettinger, Neil E. Kay, Timothy G. Call, Tait D. Shanafelt, Connie Lesnick, Curtis A. Hanson, Paolo Strati, Daniel A. Nikcevich, Betsy LaPlant
Publikováno v:
Oncotarget
// Neil E. Kay 1 , Paolo Strati 1 , Betsy R. LaPlant 1 , Jose F. Leis 2 , Daniel Nikcevich 3 , Timothy G. Call 1 , Adam M. Pettinger 1 , Connie E. Lesnick 1 , Curtis A. Hanson 1 and Tait D. Shanafelt 1 1 Mayo Clinic College of Medicine, Rochester, MN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e56056ae4586b6294428d2e1483f1117
https://doi.org/10.18632/oncotarget.13412
https://doi.org/10.18632/oncotarget.13412
Autor:
Curtis A. Hanson, Danielle M. Brander, Betsy LaPlant, Sameer A. Parikh, Paolo Strati, Asher Chanan-Khan, Mark C. Lanasa, Adam Pettinger, Wei Ding, Michael S. Conte, Neil E. Kay, Deborah A. Bowen, Tait D. Shanafelt, Jose F. Leis, Timothy G. Call
Publikováno v:
The Lancet Haematology. 3:e407-e414
Summary Background Although several consolidation strategies to prolong treatment-free survival (TFS) in chronic lymphocytic leukaemia have been investigated, most have proven either ineffective or toxic. Ofatumumab is a human type I anti-CD20 antibo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbb4468c486ebc147402125ac31b4aa7
https://doi.org/10.1016/s2352-3026(16)30064-3
https://doi.org/10.1016/s2352-3026(16)30064-3
Autor:
Betsy LaPlant, Sameer A. Parikh, Adam Pettinger, Wei Ding, Timothy G. Call, Michael J. Conte, Tait D. Shanafelt, Neil E. Kay, Deborah A. Bowen, Jose F. Leis
Publikováno v:
Expert review of hematology. 11(4)
7 regimens of pentostatin based chemoimmunotherapy (CIT) for progressive previously untreated CLL primarily with long term follow-up to update both efficacy and toxicity.Prognostic markers including assessment of IGVH and FISH status were done on all
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5802f5656ebff7fda07a4680879afd4
https://pubmed.ncbi.nlm.nih.gov/29460654
https://pubmed.ncbi.nlm.nih.gov/29460654
Autor:
Jeremy T, Larsen, Tait D, Shanafelt, Jose F, Leis, Betsy, LaPlant, Tim, Call, Adam, Pettinger, Curtis, Hanson, Charles, Erlichman, Thomas Matthew, Habermann, Craig, Reeder, Daniel, Nikcevich, Deborah, Bowen, Michael, Conte, Justin, Boysen, Charla, Secreto, Connie, Lesnick, Renee, Tschumper, Diane, Jelinek, Neil E, Kay, Wei, Ding
Publikováno v:
American journal of hematology. 92(8)
Akt is a downstream target of B cell receptor signaling and is a central regulator of CLL cell survival. We aim to investigate the safety and efficacy of the Akt inhibitor MK-2206 in combination with bendamustine and rituximab (BR) in relapsed and/or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d20386fa0ece34de8a62127da146e1cd
https://pubmed.ncbi.nlm.nih.gov/28402581
https://pubmed.ncbi.nlm.nih.gov/28402581
Autor:
Ronald P. Taylor, Clive S. Zent, Margaret A. Lindorfer, Adam Pettinger, Nisar A. Baig, Tait D. Shanafelt, Grzegorz S. Nowakowski, Betsy LaPlant, Amy K. Church
Publikováno v:
The Journal of Immunology. 192:1620-1629
Ofatumumab (OFA), a human CD20-targeting mAb, kills B lymphocytes using the innate immune system including complement-dependent cytotoxicity (CDC). The efficacy of OFA in patients with chronic lymphocytic leukemia (CLL) is limited by drug resistance,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f75fd873d8160b6f676e946487cc555
https://doi.org/10.4049/jimmunol.1302954
https://doi.org/10.4049/jimmunol.1302954